Halazepam is a benzodiazepine derivative that was marketed under the brand names Paxipam in the United States, Alapryl in Spain, and Pacinone in Portugal.
Medical uses Halazepam was used for the treatment of anxiety.
Adverse effects Adverse effects include drowsiness, confusion, dizziness, and sedation. Gastrointestinal side effects have also been reported including dry mouth and nausea.
Pharmacokinetics and pharmacodynamics Pharmacokinetics and pharmacodynamics were listed in Current Psychotherapeutic Drugs published on June 15, 1998 as follows:
Onset of action Intermediate to slow Plasma half life 14 hr for parent drug and 30-100 hr for its metabolite Peak plasma levels 1-3 hr for parent drug and 3-6 hf for its metabolite Metabolism Metabolized into desmethyldiazepam and 3-hydroxyhalazepam (in the liver) Excretion Excreted through kidneys Protein binding 98% bound to plasma protein
Regulatory Information Halazepam is classified as a schedule 4 controlled substance with a corresponding code 2762 by the Drug Enforcement Administration (DEA).
Commercial production Halazepam was invented by Schlesinger Walter in the U.S. It was marketed as an anti-anxiety agent in 1981. However, Halazepam is not commercially available in the United States because it was withdrawn by its manufacturer for poor sales.
See also Benzodiazepines Nordazepam Diazepam Chlordiazepoxide Quazepam, fletazepam, triflubazam — benzodiazepines with trifluoromethyl group attached
References
External links Inchem - Halazepam